Solfrid Hegstad
Papers
4
Total Citations
125
H-Index
4
About
Solfrid Hegstad is an analytical chemist and clinical pharmacologist whose research focuses on the development and validation of advanced chromatographic and mass spectrometric methods for therapeutic drug monitoring and toxicological analysis. Working primarily in the field of bioanalytical chemistry, Hegstad has made significant contributions to the quantification of clinically important drug classes in biological matrices, including direct oral anticoagulants (DOACs), antihypertensive agents, and substances of abuse. Her most cited work, published in 2018 with 50 citations, established a validated UHPLC-MS/MS method for simultaneously measuring four DOACs — apixaban, dabigatran, edoxaban, and rivaroxaban — in human serum, addressing a critical need for precise therapeutic monitoring in anticoagulation therapy. Her 2013 study on urine-based drug screening using UPLC-MS/MS has accumulated 46 citations, reflecting its value to forensic and clinical toxicology laboratories. Hegstad has also advanced quantification methods for antihypertensive drugs and, more recently, pioneered chiral separation techniques for R/S-methadone using supercritical fluid chromatography. Collectively, her work supports safer, more personalized pharmacotherapy by enabling accurate measurement of drugs with narrow therapeutic windows.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3Quantification of 21 antihypertensive drugs in serum using UHPLC-MS/MS25 citations · 2018
- 4